World Health Organization Issues Alert Over Critical Scarcity of Obesity Injections
Less than one in 10 individuals who could benefit from obesity jabs like Wegovy have access to them, caution the WHO as it issues its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just access to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be treated with holistic and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to widespread availability to the injections that can help people shift substantial body mass, explains the body.
Skinny Jab Supply Crisis
Even in the current best projected case, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, per the health organization.
The advice calls on nations and manufacturers to increase availability, via approaches such as voluntary licensing.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Drugs Work
These medications replicate a natural hormone to delay gastric emptying, reduce hunger and boost the sense of being full so people reduce food intake.
Individuals usually start to lose weight within a few weeks of beginning the regular doses.
Studies indicates users may put most of the weight back on after a year of halting the medication, as their usual appetite return.
Being overweight or obese raises your likelihood for developing health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts people in all nations and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.
